Structural insights into activation of antiviral NK cell responses

Immunological Reviews

Volumn 250, Issue 1, 2012, Pages 239-257

  Finton, Kathryn A ^a   Strong, Roland K ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Immunoreceptors; KIR; LILR; Natural killer cell; Structural molecular immunology; Viral evasion

Indexed keywords

CD94 ANTIGEN; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; COMPLEX FORMATION; HUMAN; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOLECULAR MIMICRY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; VIRUS IMMUNITY;

ANTIGENS, VIRAL; CYTOKINES; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; KILLER CELLS, NATURAL; MODELS, MOLECULAR; PROTEIN BINDING; RECEPTORS, NATURAL KILLER CELL; SIGNAL TRANSDUCTION; T-CELL ANTIGEN RECEPTOR SPECIFICITY; VIRUS DISEASES; VIRUSES;

EID: 84867414874     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2012.01168.x     Document Type: Article

References (185)

1. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989;320:1731-1735.
2. Bancroft GJ. The role of natural killer cells in innate resistance to infection. Curr Opin Immunol 1993;5:503-510.
3. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999;17:189-220.
4. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-640.
5. Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56 brightnatural killer (NK) cells: an important NK cell subset. Immunology 2009;126:458-465.
6. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood 2009;114:2657-2666.
7. Horng T, Bezbradica JS, Medzhitov R. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nat Immunol 2007;8:1345-1352.
8. Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci USA 1989;86:2361-2364.
9. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-678.
10. Shimizu Y, DeMars R. Demonstration by class I gene transfer that reduced susceptibility of human cells to natural killer cell-mediated lysis is inversely correlated with HLA class I antigen expression. Eur J Immunol 1989;19:447-451.
11. Ljunggren HGH, Kärre KK. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 1990;11:237-244.
12. Diefenbach A, Raulet DH. Strategies for target cell recognition by natural killer cells. Immunol Rev 2001;181:170-184.
13. Arase H. Direct Recognition of Cytomegalovirus by Activating and Inhibitory NK Cell Receptors. Science 2002;296:1323-1326.
14. Mandelboim O, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001;409:1055-1060.
15. Stewart CA, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005;102:13224-13229.
16. Foley B, De Santis D, Lathbury L, Christiansen F, Witt C. KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. Int Immunol 2008;20:555-563.
17. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-512.
18. Bjorkman PJ. Finding the groove. Nat Immunol 2006;7:787-789.
19. Kimball JW. Introduction to Immunology. New York: Macmillan Library Reference, 1983.
20. Cohn M. The T-cell receptor mediating restrictive recognition of antigen. Cell 1983;33:657-669.
21. Shimonkevitz R, Kappler J, Marrack P, Grey H. Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J Exp Med 1983;158:303-316.
22. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329:512-518.
23. Wucherpfennig KW, et al. Polyspecificity of T cell and B cell receptor recognition. Semin Immunol 2007;19:216-224.
24. Marrack P, Scott-Browne JP, Dai S, Gapin L, Kappler JW. Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction. Annu Rev Immunol 2008;26:171-203.
25. Garcia KC, Adams JJ, Feng D, Ely LK. The molecular basis of TCR germline bias for MHC is surprisingly simple. Nat Immunol 2009;10:143-147.
26. Scott-Browne JPJ, White JJ, Kappler JWJ, Gapin LL, Marrack PP. Germline-encoded amino acids in the alphabeta T-cell receptor control thymic selection. CORD Conf Proc 2009;458:1043-1046.
27. Adams JJ, et al. T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity 2011;35:681-693.
28. Scott-Browne JP, Crawford F, Young MH, Kappler JW, Marrack P, Gapin L. Evolutionarily conserved features contribute to αβ T cell receptor specificity. Immunity 2011;35:526-535.
29. Marsh SGE, et al. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report 2002. Immunogenetics 2003;55:220-226.
30. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998;391:703-707.
31. Mandelboim O, et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 2010;184:913-922.
32. Winter CC, Long EO. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol 1997;158:4026-4028.
33. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J Exp Med 1995;181:1133-1144.
34. Gumperz JE, et al. Conserved and variable residues within the Bw4 motif of HLA-B make separable contributions to recognition by the NKB1 killer cell-inhibitory receptor. J Immunol 1997;158:5237-5241.
35. Parham P. MHC class I molecules and kirs in human history, health and survival. Nat Rev Immunol 2005;5:201-214.
36. Romero V, et al. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Mol Immunol 2008;45:2429-2436.
37. Singh R, Kaul R, Kaul A, Khan K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. World J Gastroenterol 2007;13:1770-1787.
38. López-Botet M, Angulo A, Guma M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens 2004;63:195-203.
39. Estefanía E, et al. Influence of KIR gene diversity on the course of HSV-1 infection: resistance to the disease is associated with the absence of KIR2DL2 and KIR2DS2. Tissue Antigens 2007;70:34-41.
40. Khakoo SI, Geller R, Shin S, Jenkins JA, Parham P. The D0 domain of KIR3D acts as a major histocompatibility complex class I binding enhancer. J Exp Med 2002;196:911-921.
41. Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol 2005;175:5222-5229.
42. Martin MP, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002;31:429-434.
43. Qi Y, et al. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog 2006;2:e79.
44. Alter G, et al. Differential natural killer cell mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007;204:3027-3036.
45. Gaudieri S, et al. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 2005;6:683-690.
46. Barbour JD, Sriram U, Caillier SJ, Levy JA, Hecht FM, Oksenberg JR. Synergy or independence? deciphering the interaction of HLA class I and NK Cell KIR alleles in early HIV-1 disease progression. PLoS Pathog 2007;3:e43.
47. Long BR, et al. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol 2008;82:4785-4792.
48. Bouleta S, et al. Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 2008;22:595-599.
49. Alter G, et al. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus Type 1 infection. J Virol 2009;83:6798-6805.
50. Fadda L, et al. Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules. J Virol 2011;85:5970-5974.
51. Brackenridge S, et al. An early HIV mutation within an HLA-B*57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1. J Virol 2011;85:5415-5422.
52. Alter G, et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 2011;476:96-100.
53. Fadda L, et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci USA 2010;107:10160-10165.
54. Boyington JC, Sun PD. A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol 2002;38:1007-1021.
55. Natarajan K, Dimasi N, Wang J, Mariuzza RA, Margulies DH. Structure and function of natural killer cell cell receptors: multiple molecular solutions to self, nonself discrimination. Annu Rev Immunol 2002;20:853-885.
56. Radaev SS, Sun PDP. Structure and function of natural killer cell surface receptors. Annu Rev Biophys Biomol Struct 2003;32:93-114.
57. Sun PDP. Structure and function of natural-killer-cell receptors. Immunol Res 2003;27:539-548.
58. Joyce MG, Sun PD. The structural basis of ligand recognition by natural killer cell receptors. J Biomed Biotechnol 2011;2011:1-15.
59. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-274.
60. Fan QR, Long EO, Wiley DC. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol 2001;2:452-460.
61. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 2000;405:537-543.
62. Boyington JC, Brooks AG, Sun PD. Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. Immunol Rev 2001;181:66-78.
63. Vivian JP, et al. Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature 2011;479:401-405.
64. Sharma D, et al. Dimorphic motifs in D0 and D1+D2 domains of killer cell Ig-like receptor 3DL1 combine to form receptors with high, moderate, and no avidity for the complex of a peptide derived from HIV and HLA-A*2402. J Immunol 2009;183:4569-4582.
65. Rojo SS, Wagtmann NN, Long EOE. Binding of a soluble p70 killer cell inhibitory receptor to HLA-B*5101: requirement for all three p70 immunoglobulin domains. Eur J Immunol 1997;27:568-571.
66. Gillespie GMA, Bashirova A, Dong T, McVicar DW, Rowland-Jones SL, Carrington M. Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with CD8+ T cell epitopes. AIDS Res Hum Retroviruses 2007;23:451-455.
67. Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, Lanier LL. Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol 2007;178:647-651.
68. Stewart-Jones GBE, et al. Structures of three HIV-1 HLA-B*5703-peptide complexes and identification of related HLAs potentially associated with long-term nonprogression. J Immunol 2005;175:2459-2468.
69. Cosman D, et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997;7:273-282.
70. Colonna M, et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997;186:1809-1818.
71. Volz A, Wende H, Laun K, Ziegler A. Genesis of the ILT/LIR/MIR clusters within the human leukocyte receptor complex. Immunol Rev 2001;181:39-51.
72. Barrow AD, Trowsdale J. The extended human leukocyte receptor complex: diverse ways of modulating immune responses. Immunol Rev 2008;224:98-123.
73. Nakajima H, Samaridis J, Angman L, Colonna M. Human myeloid cells express an activating ILT receptor (ILT1) that associates with Fc receptor gamma-chain. J Immunol 1999;162:5-8.
74. Brown D, Trowsdale J, Allen R. The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens 2004;64:215-225.
75. Lepin EJ, et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000;30:3552-3561.
76. Navarro F, Llano M, Bellón T, Colonna M, Geraghty DE, López-Botet M. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 1999;29:277-283.
77. Gonen-Gross T, et al. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 2003;171:1343-1351.
78. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J Immunol 1998;160:4951-4960.
79. van Hall T, Oliveira CC, Joosten SA, Ottenhoff TH. The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress. Microbes Infect 2010;12:910-918.
80. Lee N, Ishitani A, Geraghty DE. HLA-F is a surface marker on activated lymphocytes. Eur J Immunol 2010;40:2308-2318.
81. Goodridge JP, Burian A, Lee N, Geraghty DE. HLA-F complex without peptide binds to MHC class I protein in the open conformer form. J Immunol 2010;184:6199-6208.
82. Rouas-Freiss NN, Gonçalves RMR, Menier CC, Dausset JJ, Carosella EDE. Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 1997;94:11520-11525.
83. Carosella EDE, Gregori SS, Rouas-Freiss NN, LeMaoult JJ, Menier CC, Favier BB. The role of HLA-G in immunity and hematopoiesis. CORD Conf Proc 2011;68:353-368.
84. Yang Z, Bjorkman PJ. Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor. Proc Natl Acad Sci USA 2008;105:10095-10100.
85. Chapman TL, Heikema AP, West AP, Bjorkman PJ. Crystal structure and ligand binding properties of the D1D2 region of the inhibitory receptor LIR-1 (ILT2). Immunity 2000;13:727-736.
86. Chapman TL, Heikeman AP, Bjorkman PJ. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity 1999;11:603-613.
87. Wagner CS, Ljunggren H-G, Achour A. Immune modulation by the human cytomegalovirus-encoded molecule UL18, a mystery yet to be solved. J Immunol 2008;180:19-24.
88. Kaiser BK, Pizarro JC, Kerns J, Strong RK. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci USA 2008;105:6696-6701.
89. Gao X, et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001;344:1668-1675.
90. Lichterfeld M, Yu XG. The emerging role of leukocyte immunoglobulin-like receptors (LILRs) in HIV-1 infection. J Leukoc Biol 2012;91:27-33.
91. Huang J, et al. HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses. J Exp Med 2009;206:2959-2966.
92. McMichael AJ, Yvonne Jones E. First-class control of HIV-1. Science 2010;330:1488-1490.
93. Jones DC, et al. HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. J Immunol 2011;186:2990-2997.
94. Lichterfeld M, et al. A viral CTL escape mutation leading to immunoglobulin-like transcript 4 mediated functional inhibition of myelomonocytic cells. J Exp Med 2007;204:2813-2824.
95. Willcox BE, Thomas LM, Bjorkman PJ. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol 2003;4:913-919.
96. Shiroishi M, et al. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci USA 2006;103:16412-16417.
97. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J Mol Biol 2007;372:774-797.
98. Kuroki K, et al. Extensive polymorphisms of LILRB1 (ILT2, LIR1) and their association with HLA-DRB1 shared epitope negative rheumatoid arthritis. Hum Mol Genet 2005;14:2469-2480.
99. Willcox BE, Thomas LM, Chapman TL, Heikema AP, West AP, Bjorkman PJ. Crystal structure of LIR-2 (ILT4) at 1.8 A: differences from LIR-1 (ILT2) in regions implicated in the binding of the human cytomegalovirus class I MHC homolog UL18. BMC Struct Biol 2002;2:6.
100. Gruda R, et al. Intracellular cysteine residues in the tail of MHC class I proteins are crucial for extracellular recognition by leukocyte Ig-like receptor 1. J Immunol 2007;179:3655-3661.
101. Park B, et al. Human cytomegalovirus inhibits tapasin-dependent peptide loading and optimization of the MHC class I peptide cargo for immune evasion. Immunity 2004;20:71-85.
102. Browne H, Smith G, Beck S, Minson T. A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin. Nature 1990;347:770-772.
103. Fahnestock ML, Johnson JL, Feldman RM, Neveu JM, Lane WS, Bjorkman PJ. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity 1995;3:583-590.
104. Wagner CS, Rölle A, Cosman D, Ljunggren H-G, Berndt KD, Achour A. Structural elements underlying the high binding affinity of human cytomegalovirus UL18 to leukocyte immunoglobulin-like receptor-1. J Mol Biol 2007;373:695-705.
105. Cerboni C, et al. Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR-1/ILT2/CD85j. Eur J Immunol 2006;36:732-741.
106. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 1988;331:269-272.
107. Sullivan LC, et al. The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity 2007;27:900-911.
108. Brostjan C, Bellón T, Sobanov Y, López-Botet M, Hofer E. Differential expression of inhibitory and activating CD94/NKG2 receptors on NK cell clones. J Immunol Methods 2002;264:109-119.
109. Kaiser BK, Barahmand-Pour F, Paulsene W, Medley S, Geraghty DE, Strong RK. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics. J Immunol 2005;174:2878-2884.
110. Lazetic S, Chang C, Houchins JP, Lanier LL, Phillips JH. Human natural killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of CD94 and NKG2 subunits. J Immunol 1996;157:4741-4745.
111. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med 1998;187:813-818.
112. Braud VM, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795-799.
113. Brooks AG, et al. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells. J Immunol 1999;162:305-313.
114. Lee N, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA 1998;95:5199-5204.
115. Suto Y, Yabe T, Maenaka K, Tokunaga K, Tadokoro K, Juji T. The human natural killer gene complex (NKC) is located on chromosome 12p13.1-p13.2. Immunogenetics 1997;46:159-162.
116. Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991;173:1017-1020.
117. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 1998;8:693-701.
118. Braud VM, Allan DS, Wilson D, McMichael AJ. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol 1998;8:1-10.
119. Brooks CR, Elliott T, Parham P, Khakoo SI. The inhibitory receptor NKG2A determines lysis of vaccinia virus-infected autologous targets by NK cells. J Immunol 2006;176:1141-1147.
120. Bjorkstrom NK, et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011;208:13-21.
121. Tomasec P, et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000;287:1031.
122. Guma M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004;104:3664-3671.
123. Petrie EJ, et al. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence. J Exp Med 2008;205:725-735.
124. Plougastel B, Trowsdale J. Cloning of NKG2-F, a new member of the NKG2 family of human natural killer cell receptor genes. Eur J Immunol 1997;27:2835-2839.
125. Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
126. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010;235:267-285.
127. Li PP, Willie STS, Bauer SS, Morris DLD, Spies TT, Strong RKR. Crystal structure of the MHC class I homolog MIC-A, a gammadelta T cell ligand. Immunity 1999;10:577-584.
128. Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA. Nat Immunol 2001;2:443-451.
129. Radaev S, Rostro B, Brooks AG, Colonna M, Sun PD. Conformational plasticity revealed by the cocrystal structure of NKG2D and its class I MHC-like ligand ULBP3. Immunity 2001;15:1039-1049.
130. Holmes MA, Li P, Petersdorf EW, Strong RK. Structural studies of allelic diversity of the MHC class I homolog MIC-B, a stress-inducible ligand for the activating immunoreceptor NKG2D. J Immunol 2002;169:1395-1400.
131. McFarland BJ, Kortemme T, Yu SF, Baker D, Strong RK. Symmetry recognizing asymmetry: analysis of the interactions between the C-type lectin-like immunoreceptor NKG2D and MHC class I-like ligands. Structure 2003;11:411-422.
132. McFarland B, Strong S. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. Immunity 2003;19:772-774.
133. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 2000;21:228-234.
134. Cantoni C, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999;189:787-796.
135. Pessino A, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998;188:953-960.
136. Pende D, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190:1505-1516.
137. Vitale M, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998;187:2065-2072.
138. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgado A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 2001;31:2680-2689.
139. Jarahian M, et al. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. J Virol 2009;83:8108-8121.
140. Arnon TI, et al. Inhibition of the NKp30 activating receptor by pp 65 of human cytomegalovirus. Nat Immunol 2005;6:515-523.
141. De Maria A, et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007;37:445-455.
142. Ahlenstiel G, et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010;138:e2.
143. Chisholm SE, Howard K, Gómez MV, Reyburn HT. Expression of ICP0 Is sufficient to trigger natural killer cell recognition of herpes simplex virus-infected cells by natural cytotoxicity receptors. J Infect Dis 2007;195:1160-1168.
144. Fuller CL, et al. NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell Microbiol 2007;9:962-976.
145. Hershkovitz O, et al. NKp44 receptor mediates interaction of the envelope glycoproteins from the west Nile and Dengue viruses with NK Cells. J Immunol 2009;183:2610-2621.
146. Chisholm SE, Reyburn HT. Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors. J Virol 2006;80:2225-2233.
147. Foster CE. Crystal structure of the human natural killer (NK) cell activating receptor NKp46 reveals structural relationship to other leukocyte receptor complex immunoreceptors. J Biol Chem 2003;278:46081-46086.
148. Ponassi M, et al. Structure of the human NK cell triggering receptor NKp46 ectodomain. Biochem Biophys Res Comm 2003;309:317-323.
149. Cantoni C, et al. The three-dimensional structure of the human NK cell receptor NKp44, a triggering partner in natural cytotoxicity. Structure 2003;11:725-734.
150. Joyce MG, Tran P, Zhuravleva MA, Jaw J, Colonna M, Sun PD. Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proc Natl Acad Sci USA 2011;108:6223-6228.
151. Mavoungou E, Held J, Mewono L, Kremsner PG. A duffy binding-like domain is involved in the NKp30-mediated recognition of plasmodiumfalciparum-parasitized erythrocytes by natural killer cells. J Infect Dis 2007;195:1521-1531.
152. Pogge von Strandmann E, et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007;27:965-974.
153. Hecht M-L, et al. Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J Proteome Res 2009;8:712-720.
154. Brandt CS, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med 2009;206:1495-1503.
155. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 2001;410:604-608.
156. Stamper CC, et al. Crystal structure of the B7-1/CTLA-4complex that inhibits humanimmune responses. Nature 2001;410:608-611.
157. Arnon TI. The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood 2004;103:664-672.
158. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000;69:531-569.
159. Mao H, et al. Inhibition of human natural killer cell activity by influenza virions and hemagglutinin. J Virol 2010;84:4148-4157.
160. Elliott JM, Yokoyama WM. Unifying concepts of MHC-dependent natural killer cell education. Trends Immunol 2011;32:364-372.
161. Orr MT, Lanier LL. Natural killer cell licensing during viral infection. Adv Exp Med Biol 2011;780:37-44.
162. LisniÄ VJ, Krmpotić A, Jonjić S. Modulation of natural killer cell activity by viruses. Curr Opin Microbiol 2010;13:530-539.
163. Thomas M, et al. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc Natl Acad Sci USA 2008;105:1656-1661.
164. Wolan DW, et al. Crystal structure of the murine NK cell-activating receptor NKG2D at 1.95 A. Nat Immunol 2001;2:248-254.
165. Li P, McDermott G, Strong RK. Crystal structures of RAE-1beta and its complex with the activating immunoreceptor NKG2D. Immunity 2002;16:77-86.
166. Oliviero B, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009;137:e7.
167. Call ME, Wucherpfennig KW, Chou JJ. The structural basis for intramembrane assembly of an activating immunoreceptor complex. Nature 2010;11:1023-1029.
168. Fausther-Bovendo H, et al. HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on CD4+ T cells. AIDS 2009;23:1077-1087.
169. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc Natl Acad Sci USA 1993;90:12000-12004.
170. Jarahian M, et al. Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog 2011;7:e1002195.
171. Welte S, Kuttruff S, Waldhauer I, Steinle A. Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol 2006;7:1334-1342.
172. Askar M, et al. Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients. Liver Transpl 2009;15:1557-1563.
173. Saulquin X, Gastinel LN, Vivier E. Crystal structure of the human natural killer cell activating receptor KIR2DS2 (CD158j). J Exp Med 2003;197:933-938.
174. Katz G, Markel G, Mizrahi S, Arnon TI, Mandelboim O. Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 4. J Immunol 2001;166:7260-7267.
175. Zúñiga J, et al. Protective KIR-HLA interactions for HCV infection in intravenous drug users. Mol Immunol 2009;46:2723.
176. Graef T, et al. KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A*11 while diminishing avidity for HLA-C. J Exp Med 2009;206:2557-2572.
177. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999;189:1093-1100.
178. Boyington JC, Riaz AN, Patamawenu A, Coligan JE, Brooks AG, Sun PD. Structure of CD94 reveals a novel C-type lectin fold: implications for the NK cell-associated CD94/NKG2 receptors. Immunity 1999;10:75-82.
179. Nattermann JJ, et al. HIV-1 infection leads to increased HLA-E expression resulting in impaired function of natural killer cells. Antivir Ther 2005;10:95-107.
180. Jinushi M, et al. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. J Immunol 2004;173:6072-6081.
181. Fan QR, Mosyak L, Winter CC, Wagtmann N, Long EO, Wiley DC. Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors (KIR2DL1). Nature 1997;389:96-100.
182. Snyder GA, Brooks AG, Sun PD. Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Proc Nat Acad Sci USA 1999;96:3864-3869.
183. Moraru M, et al. Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity. J Immunol 2012;188:4412-4420.
184. Maenaka K, Juji T, Stuart DI, Jones EY. Crystal structure of the human p58 killer cell inhibitory receptor (KIR2DL3) specific for HLA-Cw3-related MHC class I. Structure 1999;7:391-398.
185. Martin MP, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007;39:733-740.